BACKGROUND: Estimates of prostate cancer-specific mortality (PCSM) were determined after radical prostatectomy (RP) or radiation therapy (RT) in men with >or=1 high-risk factors. METHODS: The study cohort comprised 948 men who underwent RP (N = 660) or RT (N = 288) for localized prostate cancer between 1988 and 2004 and had at least 1 of the following high-risk factors: a prostate-specific antigen (PSA) velocity >2 ng/mL/year during the year before diagnosis, a biopsy Gleason score of >or=7, a PSA level of >or=10 ng/mL, or clinical category T2b or high disease. Grays regression was used to evaluate whether the number and type of high-risk factors were associated with time to PCSM. RESULTS: Multiple determinants of high risk were found to be significantly associated with a shorter time to PCSM after RP (P < .001) or RT (P <or= .001). The solitary presence of a PSA velocity >2 ng/mL/year was associated with an increased risk of PCSM after RP (hazards ratio [HR] of 7.3; 95% confidence interval [95% CI], 1.0-59 [P = .05]) or RT (HR of 12.1; 95% CI, 1.4-105 [P = .02]) when compared with men with any other single high-risk factor. CONCLUSIONS: Men with a PSA velocity >2 ng/mL/year had a significantly higher risk of PCSM compared with men who had any other single high-risk factor. These men should be considered for randomized trials evaluating the impact on PCSM from adding systemic agents to standards of care for men with high-risk PC. Copyright (c) 2007 American Cancer Society.
BACKGROUND: Estimates of prostate cancer-specific mortality (PCSM) were determined after radical prostatectomy (RP) or radiation therapy (RT) in men with >or=1 high-risk factors. METHODS: The study cohort comprised 948 men who underwent RP (N = 660) or RT (N = 288) for localized prostate cancer between 1988 and 2004 and had at least 1 of the following high-risk factors: a prostate-specific antigen (PSA) velocity >2 ng/mL/year during the year before diagnosis, a biopsy Gleason score of >or=7, a PSA level of >or=10 ng/mL, or clinical category T2b or high disease. Grays regression was used to evaluate whether the number and type of high-risk factors were associated with time to PCSM. RESULTS: Multiple determinants of high risk were found to be significantly associated with a shorter time to PCSM after RP (P < .001) or RT (P <or= .001). The solitary presence of a PSA velocity >2 ng/mL/year was associated with an increased risk of PCSM after RP (hazards ratio [HR] of 7.3; 95% confidence interval [95% CI], 1.0-59 [P = .05]) or RT (HR of 12.1; 95% CI, 1.4-105 [P = .02]) when compared with men with any other single high-risk factor. CONCLUSIONS:Men with a PSA velocity >2 ng/mL/year had a significantly higher risk of PCSM compared with men who had any other single high-risk factor. These men should be considered for randomized trials evaluating the impact on PCSM from adding systemic agents to standards of care for men with high-risk PC. Copyright (c) 2007 American Cancer Society.
Authors: Phillip M Pierorazio; Ashley E Ross; Misop Han; Jonathan I Epstein; Alan W Partin; Edward M Schaeffer Journal: BJU Int Date: 2011-08-22 Impact factor: 5.588
Authors: Xiaoye Zhu; Peter C Albertsen; Gerald L Andriole; Monique J Roobol; Fritz H Schröder; Andrew J Vickers Journal: Eur Urol Date: 2011-11-24 Impact factor: 20.096
Authors: Stefan Carlsson; Fredrik Jäderling; Anna Wallerstedt; Tommy Nyberg; Johan Stranne; Thordis Thorsteinsdottir; Sigrid V Carlsson; Anders Bjartell; Jonas Hugosson; Eva Haglind; Gunnar Steineck Journal: BJU Int Date: 2016-03-18 Impact factor: 5.588
Authors: Ofer Yossepowitch; Scott E Eggener; Angel M Serio; Brett S Carver; Fernando J Bianco; Peter T Scardino; James A Eastham Journal: Eur Urol Date: 2007-10-12 Impact factor: 20.096
Authors: Farzana A Faisal; Debasish Sundi; Phillip M Pierorazio; Mark W Ball; Elizabeth B Humphreys; Misop Han; Jonathan I Epstein; Alan W Partin; H Ballentine Carter; Trinity J Bivalacqua; Edward M Schaeffer; Ashley E Ross Journal: BJU Int Date: 2014-08-13 Impact factor: 5.588